Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1976 Aug;52(610):481–486. doi: 10.1136/pgmj.52.610.481

An eighteen months' study of the clinical response to metoprolol, a selective beta1-receptor blocking agent, in patients with angina pectoris.

M B Comerford, E M Besterman
PMCID: PMC2496449  PMID: 10564

Abstract

Following an initial dose response study, metoprolol, a selective beta1-receptor blocking agent, was compared with equipotent dosages of propanolol in a double blind cross-over study, including exercise tolerance tests, on fourteen patients with angina pectoris. Long term therapy with metoprolol then followed until the seventy-second week. Patients performed 8% more total work on metoprolol with 15% more work recorded up to the onset of S-T depression, in comparison with propranolol. In the long term, ther was no significant difference in work performed when the daily dosage of metoprolol was changed from a q.i.d. to a b.d. regime. Metoprolol was shown to be an effective anti-anginal compound with good tolerance and safety, with gradual improvement in underlying myocardial ischaemia during long term treatment.

Full text

PDF
482

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ablad B., Carlsson E., Ek L. Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. Life Sci I. 1973 Feb 1;12(3):107–119. doi: 10.1016/0024-3205(73)90368-8. [DOI] [PubMed] [Google Scholar]
  2. Adolfsson L., Areskog N. H., Furberg C., Johnsson G. Effects of single doses of alprenolol and two cardioselective beta-blockers (H 87-07 and H 93-26) on exercise-induced angina pectoris. Eur J Clin Pharmacol. 1974;7(2):111–118. doi: 10.1007/BF00561324. [DOI] [PubMed] [Google Scholar]
  3. Aström H., Vallin H. Effect of a new beta-adrenergic blocking agent, ICI 66o82, on exercise haemodynamics and airway resistance in angina pectoris. Br Heart J. 1974 Dec;36(12):1194–1200. doi: 10.1136/hrt.36.12.1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boudoulas H., Cobb T. C., Leighton R. F., Wilt S. M. Myocardial lactate production in patients with angina-like chest pain and angiographically normal coronary arteries and left ventricle. Am J Cardiol. 1974 Oct 3;34(5):501–505. doi: 10.1016/0002-9149(74)90118-0. [DOI] [PubMed] [Google Scholar]
  5. Dunlop D., Shanks R. G. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968 Jan;32(1):201–218. doi: 10.1111/j.1476-5381.1968.tb00444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ervik M. Quantitative determination of metoprolol in plasma and urine by gas chromatography. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):136–144. doi: 10.1111/j.1600-0773.1975.tb03330.x. [DOI] [PubMed] [Google Scholar]
  7. Felix R. H., Ive F. A., Dahl M. G. Cutaneous and ocular reactions to practolol. Br Med J. 1974 Nov 9;4(5940):321–324. doi: 10.1136/bmj.4.5940.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hartley L. H. Editorial: Value of clinical exercise testing. N Engl J Med. 1975 Aug 21;293(8):400–401. doi: 10.1056/NEJM197508212930809. [DOI] [PubMed] [Google Scholar]
  9. Heterington D. J., Comerford M. B., Nyberg G., Besterman E. M. Comparison of two adrenergic beta-receptor blocking agents, alprenolol and propranolol, in treatment of angina pectoris. Br Heart J. 1973 Mar;35(3):320–333. doi: 10.1136/hrt.35.3.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jackson G., Atkinson L., Oram S. Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris. Br Med J. 1975 Mar 29;1(5960):708–712. doi: 10.1136/bmj.1.5960.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kattus A. A. Exercise electrocardiography: recognition of the ischemic response, false positive and negative patterns. Am J Cardiol. 1974 May 20;33(6):721–731. doi: 10.1016/0002-9149(74)90212-4. [DOI] [PubMed] [Google Scholar]
  12. Redwood D. R., Epstein S. E. Uses and limitations of stress testing in the evaluation of ischemic heart disease. Circulation. 1972 Dec;46(6):1115–1131. doi: 10.1161/01.cir.46.6.1115. [DOI] [PubMed] [Google Scholar]
  13. SODI-PALLARES D., TESTELLI M. R., FISHLEDER B. L., BISTENI A., MEDRANO G. A., FRIEDLAND C., DE MICHELI A. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962 Feb;9:166–181. doi: 10.1016/0002-9149(62)90035-8. [DOI] [PubMed] [Google Scholar]
  14. Windsor W. O., Durrein F., Dyer N. H. Fibrinous peritonitis: a complication of practolol therapy. Br Med J. 1975 Apr 12;2(5962):68–68. doi: 10.1136/bmj.2.5962.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975 Mar 15;1(5958):595–598. doi: 10.1136/bmj.1.5958.595. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES